Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Max Hardy Werbin"'
Autor:
Claire Olingy, Ahmad Alimadadi, Daniel J. Araujo, David Barry, Norma A. Gutierrez, Max Hardy Werbin, Edurne Arriola, Sandip Pravin Patel, Christian H. Ottensmeier, Huy Q. Dinh, Catherine C. Hedrick
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths globally. Immune checkpoint blockade (ICB) has transformed cancer medicine, with anti-programmed cell death protein 1 (anti-PD-1) therapy now well-utilized for treati
Externí odkaz:
https://doaj.org/article/1269b37320e04f1fb1151f73ee5673c6
Autor:
Max Hardy-Werbin, José Maria Maiques, Marcos Busto, Isabel Cirera, Alfons Aguirre, Nieves Garcia-Gisbert, Flavio Zuccarino, Santiago Carbullanca, Luis Alexander Del Carpio, Didac Ramal, Ángel Gayete, Jordi Martínez-Roldan, Albert Marquez-Colome, Beatriz Bellosillo, Joan Gibert
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The rapid spread of the severe acute respiratory syndrome coronavirus 2 led to a global overextension of healthcare. Both Chest X-rays (CXR) and blood test have been demonstrated to have predictive value on Coronavirus Disease 2019 (COVID-19
Externí odkaz:
https://doaj.org/article/3ae2a8c98443459290162cd00ba2c0fd
Autor:
Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, Álvaro Taus, Lara Nonell, Xavier Durán, Xavier Villanueva, Deborah Joseph-Pietras, Luke Nolan, Sarah Danson, Richard Griffiths, Miguel Lopez-Botet, Ana Rovira, Joan Albanell, Christian Ottensmeier, Edurne Arriola
Publikováno v:
OncoImmunology, Vol 8, Iss 6 (2019)
Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of S
Externí odkaz:
https://doaj.org/article/a1ead5721a954201bf1312e65ba8f204
Autor:
Maria Milagro Montero, Max Hardy-Werbin, Soledad Gonzalez-Gallardo, Erica Torres, Rebeca Rueda, Irene Hannet, James T. Kirk, Thomas D. Yager, Krupa Navalkar, Maria del Mar Arenas, Itziar Arietta-Aldea, Silvia Castañeda, Joan Gómez-Junyent, Silvia Gómez-Zorrilla, Roberto Guerri-Fernandez, Francisca Sanchez-Martinez, Immaculada López-Montesinos, Ivan Pelegrín, Elena Sendra, Luisa Sorlí, Judith Villar-García, Beatriz Bellosillo, Juan Pablo Horcajada
Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. The aim of this study was to evaluate SeptiCyte RAPID, a host immune response assay (Immunexpress, Seattle USA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bacad168c8addf085a1d542d88719ce
http://hdl.handle.net/10230/55674
http://hdl.handle.net/10230/55674
Autor:
Maria Milagro Montero, Max Hardy-Werbin, Soledad Gonzalez Gallardo, Erica Torres, Rebeca Rueda, Irene Hannet, James T Kirk, Thomas D Yager, Krupa Navalkar, Maria del Mar Arenas, Itziar Arietta-Aldea, Silvia Castañeda, Joan Gómez-Junyent, Silvia Gómez-Zorrilla, Roberto Guerri-Fernández, Francisca Sanchez-Martinez, Immaculada López-Montesinos, Ivan Pelegrín, Elena Sendra, Luisa Sorlí, Judith Villar-García, Beatriz Bellosillo Paricio, Juan Pablo Horcajada
Rationale: Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. Objective: Evaluation of SeptiCyte RAPID, a host immune response assay (Immunexpress, Seattle USA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b79c6ac89e6adc1839ec7f8eff9b7157
https://doi.org/10.21203/rs.3.rs-1942658/v1
https://doi.org/10.21203/rs.3.rs-1942658/v1
Autor:
Juan Jose Garcia, Sofia España, Max Hardy-Werbin, Iris Teruel, Dania Carballo, Jose Maria Velarde, Elisabeth Montprade, Vanesa Quiroga, Marc Cucurull, Carlos Erasun, Margarita Romeo, Beatriz Cirauqui, Mireia Margeli, Juan Carlos Pardo, Eudald Felip
Publikováno v:
Scientific Reports
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Scientific Reports, Vol 9, Iss 1, Pp 1-7 (2019)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Scientific Reports, Vol 9, Iss 1, Pp 1-7 (2019)
T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61deda5d3a13921ee59c91d2dbfce1a3
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2811
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2811
Autor:
Vanesa Quiroga García, David López Sisamon, Mireia Margelí Vila, Max Hardy-Werbin, Beatriz Cirauqui, Ana Belén Blanca, Lyan Tobey Robaina
Publikováno v:
Anti-Cancer Drugs. 27:464-469
Cancer patients with severe renal dysfunction represent a challenge for the physician. This is the first case report on the use of denosumab in a dialysis patient with bone metastases. We present the clinical case of a 45-year-old woman who had hepat
Autor:
M Cucurull Salamero, M. Margeli Vila, I ruel Te García, Max Hardy-Werbin, E Felip Falgas, C. Erasun Lecuona, J J García Mosquera
Publikováno v:
Annals of Oncology. 30:v96
Background The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general population. Tamoxifen, chemotherapy and breast irradiation are associated with an increased risk of SPM. The
Autor:
Jose Luis Cuadra-Urteaga, Cristina Buges, Vanesa Quiroga, Laia Vilà Martinez, Rafael Rosell, Yolanda Luis, Eli Nancy Perez, Laia Capdevila, Beatriz Gutierrez, Iris Teruel, Sara Cros, Anna Estival, Teresa Moran, Alberto Indacochea, Sara Ahlal, Josep Jové, Enric Carcereny Costa, N. Pardo, Max Hardy-Werbin, Maria de los Llanos Gil Gil Moreno
Publikováno v:
Journal of Clinical Oncology. 33:e22139-e22139
e22139 Background: During the last years, new predictive and less frequent biomarkers have emerged in NSCLC, such as ROS1 translocation (ROS1t), HER2 mutations (HER2m) and BRAF mutations (BRAFm). W...
Autor:
Sergi Clavé, Jennifer B. Jackson, Marta Salido, Jacob Kames, Kelly M. R. Gerding, Ellen L. Verner, Eric F. Kong, Elizabeth Weingartner, Joan Gibert, Max Hardy-Werbin, Pedro Rocha, Xènia Riera, Erica Torres, James Hernandez, Gustavo Cerqueira, Donna Nichol, John Simmons, Álvaro Taus, Lara Pijuan, Beatriz Bellosillo, Edurne Arriola
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionNext-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor’s molecular landscape. However, further e
Externí odkaz:
https://doaj.org/article/80540fee92c8444d8cf2e823ff47914c